Electrophysiological study of the response of ventral tegmental area non-dopaminergic neurons to nicotine after concurrent blockade of orexin receptor-2 and cannabinoid receptors-1.


Journal

Brain research
ISSN: 1872-6240
Titre abrégé: Brain Res
Pays: Netherlands
ID NLM: 0045503

Informations de publication

Date de publication:
15 09 2019
Historique:
received: 12 01 2019
revised: 14 05 2019
accepted: 30 05 2019
pubmed: 4 6 2019
medline: 26 9 2020
entrez: 3 6 2019
Statut: ppublish

Résumé

The ventral tegmental area (VTA) is a key brain region, involved in the dependency on nicotine. Studies have shown that orexin and cannabinoids are likely to play an important role in nicotine dependency. In this study, the effect of orexin receptor-2 (OX2R) and cannabinoid receptor-1 (CB1R) blockade were investigated in response to nicotine in male rats, on the neural activity of VTA. Nicotine was injected subcutaneously and its effect on the firing of VTA non-dopaminergic (ND) neurons was investigated, using in vivo extracellular single unit recording. Nicotine increased the ND neuronal activity of the VTA. AM251 (0.18, 0.9, 1.8 nmol/0.3 µL), as a selective cannabinoid CB1R antagonist, and TCS-OX2-29 (0.5, 1, 5 nmol/0.3 µL), as a selective OX2R antagonist, individually or simultaneously were microinjected into the VTA. The results revealed that blockade of OX2R and CB1R in the VTA could prevent the increased firing rate, caused by nicotine. Concurrent administration of TCS-OX2-29 and AM251 could decrease responsiveness of VTA-ND neurons to nicotine, but it did not show a greater response than their single application. Because the synergistic effect was not observed in the simultaneous blockade of these two receptors, therefore, in order to detect the interactions of these two receptors, further studies are needed in the field of intracellular signaling.

Identifiants

pubmed: 31153915
pii: S0006-8993(19)30297-5
doi: 10.1016/j.brainres.2019.05.042
pii:
doi:

Substances chimiques

1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-((4-pyridinylmethyl)amino)-1-butanone 0
Cannabinoids 0
Isoquinolines 0
Orexin Receptor Antagonists 0
Orexin Receptors 0
Piperidines 0
Pyrazoles 0
Pyridines 0
Receptors, Cannabinoid 0
AM 251 3I4FA44MAI
Nicotine 6M3C89ZY6R

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

176-182

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Fatemeh Azizi (F)

Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Reza Fartootzadeh (R)

Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Hojjatallah Alaei (H)

Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.

Parham Reisi (P)

Department of Physiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Electronic address: p_reisi@med.mui.ac.ir.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH